IO Biotech announced updated efficacy data and subgroup analyses from the MM1636 Phase 1/2 clinical trial evaluating IO102-IO103 as investigational agents in metastatic melanoma in an e-poster presentation at the American Association of Cancer Research conference (AACR), being held April 8-13, 2022 in New Orleans, Louisiana. Data highlights from the e-poster titled, “High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab” are outlined below: All 30 patients were evaluated after completing the IDO-PD-L1 vaccination schedule in combination with nivolumab as of the December 1, 2021 data cut-off and after a median follow up of 2.7 years; the three-year OS probability was 73%; the median progression free survival (mPFS) was 25.3 months. Confirmed overall response rate was 73% with 46.7% of patients obtaining complete responses in poor prognosis patients; a response rate of 81.8% (mPFS: 30.9 months) was seen in patients with elevated baseline LDH-levels; in patients classified as M1c at baseline response rate was 88.2%, (mPFS: 25.6 months); In a subgroup analysis, a response rate of 94.1% was observed in PD-L1+ patients (mPFS: 30.9 months) and 61.5% in PD-L1(-) patients (mPFS: 7.2 months); Immune-related adverse events were comparable to those in patients receiving nivolumab monotherapy. No additional toxicity was observed in poor prognosis patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.